RT Journal Article
T1 Survival of dogs with pituitary‐dependent hyperadrenocorticism treated twice daily with low doses of trilostane
A1 García San José, Paula
A1 Arenas Bermejo, Carolina
A1 Alonso Miguel, Daniel
A1 González Sanz, Sandra
A1 Clares Moral, Irene
A1 Portero Fuentes, Miriam
A1 Pérez Alenza, María De Los Dolores
AB BackgroundTwice daily low trilostane doses have proven to be effective to manage canine Cushing's syndrome. However, survival and prognostic factors in dogs treated with this protocol have not been evaluated. The aim of the study was to evaluate survival and prognostic factors, including systolic blood pressure (SBP) at diagnosis, in dogs with pituitary-dependent hypercortisolism (PDH) treated with low trilostane doses.MethodsMedical records of 91 dogs newly diagnosed with PDH initially treated with 0.2–1.1 mg/kg of trilostane twice daily were retrospectively included. Survival times were calculated using the Kaplan–Meier estimator. Univariable and multivariable analysis were performed using the Cox proportional hazard regression analysis.ResultsOverall, median survival was 998 days (range 26–1832 days, 95% confidence interval = 755–1241 days). In the multivariable analysis, age (hazard ratio [HR] = 1.337, p < 0.001), presence of calcinosis cutis (HR = 5.271, p < 0.001), body condition score (BCS) ≤3/9 (HR = 8.100, p < 0.001) and higher platelet count (HR = 1.002, p = 0.022) were negatively correlated with survival. SBP was not associated with survival.ConclusionsLow-dose trilostane treatment twice daily provides slightly longer survival than previously reported for dogs with PDH treated once or twice daily at higher doses. Older age, presence of calcinosis cutis, low BCS and higher platelet count, but not systemic hypertension, are predictive of poorer prognosis in dogs with PDH.
PB BVA: British Veterinary Association
SN 0042-4900
YR 2022
FD 2022-03-15
LK https://hdl.handle.net/20.500.14352/71481
UL https://hdl.handle.net/20.500.14352/71481
LA eng
NO CRUE-CSIC (Acuerdos Transformativos 2022)
NO Royal Canin
DS Docta Complutense
RD 2 may 2024